ARO-DUX4

iStock, Galeanu Mihai Sarepta Therapeutics has put in place several initiatives to help its gene therapy Elevidys return to growth, but recovery will take a long time, according to company executives. Sarepta Therapeutics is taking a conservative approach to predicting the future and wants others to do the same. The embattled biotech asked analysts on a Q1 earnings call Wednesday to “exercise prudence” before raising their expectations and projections for its recovery. This is despite CEO Doug Ingram telling investors that the company is “in a great place” financially, with enough resources to keep advancing its pipeline without having to sell off stock for capital. Sarpeta is coming off a difficult 2025. Its flagship product, the Duchenne muscular dystrophy gene therapy Elevidys, was linked to one patient death in March 2025 and to another in June that year. The mortalities kicked off a back-and-forth with the FDA, which after a third death linked to a related product asked the company to stop U.S. shipments of Elevidys. Sarepta initially said no but eventually agreed . After less than two weeks, Elevidys shipments resumed , with the FDA later adding a boxed warning that flags a risk of death. The regulator also limited the drug’s use only to those who are able to walk and are 4 years of age and older. Earnings Sarepta, Amylyx and Neumora look ahead to key catalysts as Q1 earnings roll in As Q1 earnings arrive, three biotechs have big quarters ahead, with two—Amylyx and Neumora Therapeutics—betting at least partly on novel assets for obesity. May 5, 2026 · 5 min read · Heather McKenzie Read more In the aftermath of the Sarepta saga, which also saw the short-lived exit of then-biologics chief Vinay Prasad, demand for Elevidys has been slow to pick back up. In Q1 of this year, the gene therapy made $102 million in revenue, down 7% since Q4 2025, according to Jefferies, but still beating the consensus forecast of $96 million. To help re-energize the market, Sarepta has rolled out a slew of aggressive commercial initiatives, Ingram said on Wednesday’s call. These include expanding the company’s salesforce to more actively engage doctors and rolling out new educational resources meant for both patients and physicians. These new materials, according to Chief Commercial Officer Patrick Moss, incorporate new long-term efficacy and safety data from the Phase 3 EMBARK study, which in January found that Elevidys preserved muscle and functional performance over three years of follow-up. The effort is paying off, Ingram said, but the path to Elevidys’ return to growth will be a long one. Moss agreed: “Last quarter, I said we are seeing green shoots—early signals that give us confidence we are headed in the right direction—and the team is squarely focused on delivering the efficacy message to drive demand,” he told investors. Still, “it will take time to see the potential impact of my team’s actions reflected in sales.” Gene therapy After Mortality-Marred Year, Sarepta Looks Ahead to Catalyst-Rich 2026 Jefferies analysts forecast a $1 billion market opportunity for each of Sarepta’s siRNA programs for facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1. January 13, 2026 · 2 min read · Tristan Manalac Read more While Elevidys commanded most of the analysts’ interest during Sarepta’s call, the company also provided key updates for its siRNA pipeline. Sarepta is building up to additional data for SRP-1001 in facioscapulohumeral muscular dystrophy type 1 (FSHD) and SRP-1003 in myotonic dystrophy type 1 (DM1) in the second half of the year, according to its Wednesday release. A readout in March showed that SRP-1001 resulted in a 90% to 93% decrease in the expression of genes that are abnormally upregulated in FSHD, while SRP-1003 gained an early edge over other therapies from competing companies. These data gave Jefferies confidence in these assets. “These compounds could show superior efficacy/safety and provide less-frequent dosing” in their target indications, analysts wrote to investors on Wednesday. Elevidys pivoted to siRNA development in July last year, after the Elevidys deaths. Gene therapy Sarepta’s Not Done With Gene Therapy Yet as LGMD Asset Yields Promising Data Despite announcing a broad pivot to siRNA earlier this year, Sarepta is following through with an investigational gene therapy: its limb-girdle muscular dystrophy candidate. But the treatment’s path forward, analysts say, is highly uncertain. October 15, 2025 · 6 min read · Tristan Manalac Read more

In its latest earnings report on Thursday, Sarepta Therapeutics reported net product revenue from its gene therapy Elevidys that beat Wall Street expectations. Sales, however, continued to dip quarter over quarter, a sign some analysts say means the company is still stabilizing.Sarepta recorded $331 million in overall net product revenue during the first three months of the year, above the average analyst estimate, according to Brian Abrahams of RBC Capital Markets. Even so, the biotechnology companys shares dipped more than 10% Thursday, to trade around $20.60 apiece.Abrahams believes that uncertainties surrounding long-term growth and competitive threats should shift investor focus away from Elevidys and toward Sareptas early-stage platform of small interfering RNA therapies. There, early signals piqued Wall Streets interest. But the programs still need to prove differentiation and, as such, we believe the stock is fairly valued, Abrahams wrote in a note to clients.In a statement, Sarepta CEO Doug Ingram maintained that the company is in a position of financial strength and is able to fully fund its pipeline of research projects.Sarepta is coming off a tumultuous year that depleted a large chunk of its market value. The company faced research setbacks as well as safety concerns related to Elevidys which, until recently, was a key growth driver leading its temporary removal from the market. The Food and Drug Administration now limits the therapys use. Sales have continued to decline.Sarepta additionally laid off over a third of its staff, halted several programs, pushed off debt and dialed back prospects for Elevidys. Earlier this year, Ingram announced plans to retire by the end of 2026.The company is now betting on two siRNA drugs licensed from Arrowhead Pharmaceuticals. In March, it unveiled positive early results for the drugs, SRP-1001 and SRP-1003, which aim to treat two genetic conditions causing muscle deterioration. Results were promising, lifting shares that month, though analysts had mixed reactions to them.Sarepta said more data is expected in the second half of the year.Of Sareptas new product revenue, $102 million comes from Elevidys. Analysts had penciled in $95 million, Abrahams wrote. Revenue for Sareptas other products landed at $229 million, falling in line with expectations.Earnings per share landed at $3.16, jumping from a loss of $3.58 per share in the fourth quarter of 2025, and significantly beating some analyst forecasts of $0.90 to $0.99 per share.The company reiterated its full-year 2026 financial guidance of net product revenue between $1.2 to $1.4 billion. '